longbridge
  • Explore
    Products
    Private Wealth ManagementUS StocksSG StocksHK StocksUS OptionsUS Pre-Market OptionsETFsREITsWarrantsCash Plus
    Tools
    Longbridge SkillLongbridge AILongbridge APIPaper TradingDividend HubLongbridge Pro
  • Café
longbridge

HENLIUS

2696

43.4600.96% ( -0.420 )
Delay Closed: Nov 18, 16:08:04
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile

News

  • Shanghai Henlius Wins China Approval for Phase 1 Trial of HLX105 Cancer Treatment

    PUBT·Nov 16, 2026 at 08:32 AM
    02696-0.96%
  • Henlius drops nearly 6% to hit 52-week low

    Market Movers·Nov 16, 2026 at 01:43 AM
    02696-0.96%
  • Henlius Announces HANSIZHUANG and FUTUONING Additions to 2026 NRDL

    Tip Ranks·Nov 15, 2026 at 10:39 AM
    02696-0.96%
  • Shanghai Henlius Biotech, Inc. Class H (2696) Receives a Buy from Guotai Haitong

    Tip Ranks·Nov 11, 2026 at 05:35 AM
    02696-0.96%
  • Could Serplulimab Trial Results Alter The Investment Case For Henlius Stock?

    Simplywall·Nov 10, 2026 at 04:41 PM
    02696-0.96%
  • Shanghai Henlius Wins Australian Approval for Phase 1 Trial of HLX109

    PUBT·Nov 4, 2026 at 08:32 AM
    02696-0.96%
  • Henlius climbs 6%

    Market Movers·Nov 4, 2026 at 06:06 AM
    02696-0.96%
  • Shanghai Henlius Proposes Raising 2026 HLX01 Collaboration Cap to RMB 714 Million

    PUBT·Nov 2, 2026 at 08:33 AM
    02696-0.96%
  • Henlius hits 52-week low

    Market Movers·Nov 2, 2026 at 02:55 AM
    02696-0.96%
LongbridgeAI
© 2026 Longbridge|Terms of ServicePrivacy Policy